AddLife AB (publ) (0REZ.L) Bundle
A Brief History of AddLife AB (publ)
AddLife AB (publ) was founded in 2016 and is based in Stockholm, Sweden. The company operates within the Life Science sector, focusing primarily on providing consumables, instruments, and services for laboratories, hospitals, and diagnostic companies.
In 2017, AddLife made its first significant acquisition by purchasing the company, Vitec, for approximately SEK 80 million. This acquisition enhanced AddLife's portfolio in medical technology and diagnostic services.
By 2019, AddLife reported net sales of approximately SEK 1.5 billion, reflecting a growth of about 19% from SEK 1.26 billion in 2018. The operating profit for 2019 reached around SEK 227 million, yielding an EBIT margin of approximately 15.1%.
In 2020, driven by the COVID-19 pandemic, AddLife's business experienced a notable upturn. The company’s sales increased to approximately SEK 2.07 billion, an increase of 38% compared to 2019. Operating profit increased to SEK 326 million, reflecting an EBIT margin of 15.7%.
During 2021, AddLife continued its expansion strategy, acquiring various companies, including the Swedish diagnostics company, LMG, in a transaction valued at approximately SEK 30 million. The company’s sales for 2021 reached around SEK 2.3 billion, with operating profit at SEK 410 million.
| Year | Net Sales (SEK billion) | Operating Profit (SEK million) | EBIT Margin (%) | Acquisitions |
|---|---|---|---|---|
| 2018 | 1.26 | 205 | 16.3 | N/A |
| 2019 | 1.5 | 227 | 15.1 | Acquisition of Vitec |
| 2020 | 2.07 | 326 | 15.7 | N/A |
| 2021 | 2.3 | 410 | 17.8 | Acquisition of LMG |
In 2022, AddLife reported net sales of approximately SEK 2.6 billion, indicating steady growth. The operating profit rose to SEK 470 million, yielding an EBIT margin of 18.1%.
As of Q2 2023, preliminary figures suggest that AddLife's sales are approximately SEK 1.4 billion. The company continues to expand its market presence with strategic acquisitions and investments in innovative life science technologies.
Overall, AddLife AB (publ) has shown consistent growth, characterized by an increasing revenue stream and strategic acquisitions enhancing its market position in the life sciences sector.
A Who Owns AddLife AB (publ)
AddLife AB (publ) is a prominent player in the life science industry, primarily engaged in the distribution of products and services for the health care sector. Understanding the ownership structure of AddLife is essential for investors and analysts assessing its market position.
As of the latest available data from October 2023, AddLife AB has a diverse ownership base, including institutional investors, mutual funds, and private shareholders. The company is listed on the Nasdaq Stockholm exchange, further enhancing transparency regarding its ownership.
| Owner Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 34.5% | 7,500,000 |
| Mutual Funds | 25.1% | 5,500,000 |
| Private Individuals | 20.3% | 4,400,000 |
| Corporate Investors | 10.0% | 2,200,000 |
| Other Stakeholders | 10.1% | 2,300,000 |
The largest institutional shareholders include asset management firms and pension funds, which are critical in influencing corporate governance and strategic decisions. For instance, the largest single shareholder reported is Första AP-fonden (the First Swedish National Pension Fund), holding approximately 8.5% of the total shares.
In terms of financial performance, AddLife reported a revenue of SEK 1.4 billion in Q2 2023, which marked an increase of 12% compared to the previous year. The company’s operating profit was recorded at SEK 180 million, demonstrating a robust operating margin of 12.9%.
Additionally, AddLife has a market capitalization of approximately SEK 4.1 billion as of October 2023. The stock price has shown resilience, trading at around SEK 235 per share, reflecting a year-to-date growth of 15%.
Ownership dynamics in AddLife AB will be crucial as the company navigates the evolving life science sector, particularly in terms of expanding its product offerings and exploring new markets. Keeping an eye on the key shareholders and their movements could provide insights into the future direction of the company.
AddLife AB (publ) Mission Statement
AddLife AB (publ) operates within the life sciences sector, focusing on products and services that improve healthcare. Their mission statement reflects a commitment to enhancing the quality of life through innovation and comprehensive solutions for healthcare providers. A key component of their mission is to be a reliable partner in the healthcare industry by providing high-quality products and services.
The company aims to distribute and develop products that support diagnostics, research, and monitoring. They emphasize sustainability and the importance of responsible business practices, aligning their operations with global health trends and demands.
Key Elements of the Mission Statement
-
Partnerships: Building robust relationships with healthcare providers to understand their needs.
-
Innovation: Continuously developing new products and services to improve patient outcomes.
-
Quality: Ensuring all products meet high standards of efficacy and safety.
-
Sustainability: Committing to environmentally responsible practices.
Financial Overview
- Partnerships: Building robust relationships with healthcare providers to understand their needs.
- Innovation: Continuously developing new products and services to improve patient outcomes.
- Quality: Ensuring all products meet high standards of efficacy and safety.
- Sustainability: Committing to environmentally responsible practices.
Financial Overview
As of the latest financial reports for Q3 2023, AddLife AB reported the following revenue and growth metrics:
| Metric | Value (SEK million) | Growth Rate YoY (%) |
|---|---|---|
| Net Sales | 1,400 | 15 |
| EBITDA | 350 | 12 |
| Net Profit | 200 | 10 |
In terms of profitability, the company's gross margin stood at 50% for the fiscal year 2023. With a focus on expansion, AddLife AB has invested approximately 100 million SEK into R&D in 2023, reflecting their commitment to innovation and maintaining a competitive edge in the market.
Furthermore, AddLife AB has a strong balance sheet with total assets amounting to 2,500 million SEK and shareholders' equity of 1,500 million SEK as of September 30, 2023. This solid financial positioning supports their mission by allowing continued investment in growth and development within the life sciences industry.
Market Position and Trends
AddLife AB holds a significant position in the Nordic countries, catering to hospitals, laboratories, and healthcare facilities. The market for medical technology is projected to grow at a CAGR of 6% through 2025. This trend aligns with AddLife's mission of facilitating improved healthcare delivery via advanced solutions.
In the diagnostics segment, AddLife reported a segment revenue of 600 million SEK, showcasing a robust 18% increase year-over-year. This growth is attributed to increased demand for diagnostic solutions amidst ongoing global health challenges.
Moreover, the company is strategically focused on expanding its portfolio through acquisitions, having successfully acquired three companies in 2023, further enhancing their product offerings and market reach.
How AddLife AB (publ) Works
AddLife AB (publ) is a Swedish company primarily engaged in the life sciences sector. The company is involved in the distribution and development of various products and services for research and healthcare applications. It operates through multiple business areas, including Medical Technology, Diagnostics, and Life Science.
Business Segments
- Medical Technology: This segment focuses on providing medical devices and equipment for hospitals and clinics.
- Diagnostics: The diagnostics segment offers products for laboratory diagnostics, including reagents and testing equipment.
- Life Science: This area encompasses products and services for research and development in pharmaceuticals and biotechnology.
Financial Performance
For the fiscal year 2022, AddLife AB reported a revenue of SEK 3.1 billion, representing an increase of 10% compared to 2021.
The company had an operating profit of SEK 540 million, leading to an operating margin of 17.4%. This is indicative of efficient cost management and strong demand in its segments.
Stock Performance
As of September 2023, AddLife's stock was trading at approximately SEK 210 per share, showing a year-to-date increase of 15%. The company has a market capitalization of around SEK 6.6 billion.
Recent Acquisition and Strategy
In 2023, AddLife acquired a local distributor for medical equipment to strengthen its market presence in the Nordic region. This acquisition is expected to contribute an additional SEK 100 million in annual revenue.
Key Financial Ratios
| Financial Metric | Value |
|---|---|
| Revenue (2022) | SEK 3.1 billion |
| Operating Profit | SEK 540 million |
| Operating Margin | 17.4% |
| Stock Price (Sept 2023) | SEK 210 |
| Market Capitalization | SEK 6.6 billion |
| Year-to-Date Stock Growth | 15% |
| Expected Revenue from Acquisition | SEK 100 million |
Market Position
AddLife AB is recognized as one of the leading companies in the Nordic life sciences market. The company has a robust network, with over 50 subsidiaries in various countries. This extensive reach allows it to respond swiftly to market demands and customer needs.
Future Outlook
Looking ahead, AddLife aims to continue expanding its product offerings and geographical presence. Analysts forecast a compound annual growth rate (CAGR) of 8% for the life sciences market in the next five years, suggesting significant opportunities for growth.
How AddLife AB (publ) Makes Money
AddLife AB (publ), a Swedish company, operates primarily in the life science sector, focusing on sales of medical and laboratory equipment. Its revenue is generated through various channels, including product sales, service agreements, and consulting for healthcare institutions. The company’s business model revolves around high-margin products and solutions, mainly tailored for healthcare and laboratory markets.
In 2022, AddLife reported a revenue of SEK 2.6 billion, demonstrating a year-on-year growth of 14%. The company operates through several subsidiaries, each catering to distinct segments within the life sciences niche.
Business Segments
- Medical Technology: This segment contributes significantly to AddLife's revenue, offering a wide range of diagnostic and therapeutic equipment.
- Laboratory Solutions: Providing analytical instruments and laboratory consumables, this segment also plays a crucial role in revenue generation.
- Healthcare Services: AddLife offers maintenance and consulting services, enhancing customer retention and fostering long-term contracts.
Revenue Breakdown
| Segment | Revenue (SEK Million) | % of Total Revenue |
|---|---|---|
| Medical Technology | 1,500 | 57.7% |
| Laboratory Solutions | 800 | 30.8% |
| Healthcare Services | 300 | 11.5% |
Product sales are complemented by service agreements, which represent a consistent revenue stream. In 2022, AddLife achieved a gross margin of 50%, underscoring its focus on high-value products.
Market Position & Growth Strategy
AddLife has targeted growth through acquisitions, expanding its portfolio and market reach. In 2022, the acquisition of GML, a supplier of laboratory equipment, added an estimated SEK 200 million to the top line. The company aims for a compounded annual growth rate (CAGR) of 10% over the next five years, driven by market expansion and new product innovation.
International Revenue Streams
Approximately 30% of AddLife's revenue is generated from international markets. The company has established a strong presence in Europe, with a growing focus on North America and Asia as key regions for future growth.
Investments in R&D
AddLife allocates around 5% of its revenue to research and development. Recent innovations include advanced diagnostic equipment and digital health solutions aimed at enhancing operational efficiencies in healthcare settings.
Conclusion on Financial Health
As of Q3 2023, AddLife reported a net profit margin of 12%, reflecting its effective cost management and pricing strategy. The company's strong balance sheet supports further investments and acquisitions, ensuring sustained growth in a competitive landscape.
AddLife AB (publ) (0REZ.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.